Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability study of CSL trivalent influenza vaccine in children aged 5 to <9 years
2015-000175-27Phase 4
- Sponsor
- CSL Seqirus
- Start
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of influenza vaccine (trivalent, inactivated, split virion) and quadrivalent influenza vaccine in influenza (2 arms), sponsored by CSL Seqirus. Primary endpoint: Frequency and intensity of fever after CSL TIV.
02
Drugs
influenza vaccine (trivalent, inactivated, split virion)quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2015-000175-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000175-27.